Cancer and central nervous system disorders: protocol for an umbrella review of systematic reviews and updated meta-analyses of observational studies

[1]  Yongqing Xu,et al.  Antegrade intramedullary nail versus plate fixation in the treatment of humeral shaft fractures , 2019, Medicine.

[2]  J. Ioannidis,et al.  Systematic evaluation of the associations between environmental risk factors and dementia: An umbrella review of systematic reviews and meta-analyses , 2017, Alzheimer's & Dementia.

[3]  Alan D. Lopez,et al.  Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study , 2017, JAMA oncology.

[4]  Ashutosh Kumar Singh,et al.  Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2016, The Lancet.

[5]  O. Uthman.  Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. , 2016, Lancet.

[6]  C. Tsai,et al.  Increased risk of brain tumor in patients with Parkinson's disease: a nationwide cohort study in Taiwan , 2016, Acta neurologica Scandinavica.

[7]  B. Davis,et al.  Cardiovascular and Renal Outcomes of Renin–Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses , 2016, PLoS medicine.

[8]  M. Olfson,et al.  Premature Mortality Among Adults With Schizophrenia in the United States. , 2015, JAMA psychiatry.

[9]  Dan J Stein,et al.  Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, BDJ.

[10]  Jonathan A C Sterne,et al.  Meta-Analysis in Stata: An Updated Collection from the Stata Journal , 2015 .

[11]  Rifat Atun,et al.  Transitioning health systems for multimorbidity , 2015, The Lancet.

[12]  Shi Yuan Tang,et al.  Inverse relationship between cancer and Alzheimer’s disease: a systemic review meta-analysis , 2015, Neurological Sciences.

[13]  Pan‐Chyr Yang,et al.  Association Between Parkinson Disease and Risk of Cancer in Taiwan. , 2015, JAMA oncology.

[14]  Nobhojit Roy,et al.  The Global Burden of Cancer 2013. , 2015, JAMA oncology.

[15]  J. Ioannidis,et al.  Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses , 2015, The Lancet Neurology.

[16]  D. Moher,et al.  The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: protocol for a systematic review and network meta-analysis of randomized controlled trials , 2015, Systematic Reviews.

[17]  Tzeng-Ji Chen,et al.  Risk of cancer in children, adolescents, and young adults with autistic disorder. , 2015, The Journal of pediatrics.

[18]  T. Fahey,et al.  Managing patients with multimorbidity in primary care , 2015, BMJ : British Medical Journal.

[19]  J. Ioannidis,et al.  Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies , 2015, BMJ : British Medical Journal.

[20]  Y. Baruch,et al.  Risk of prostate cancer in patients with schizophrenia. , 2014, Comprehensive psychiatry.

[21]  M. Goldacre,et al.  Differential risks of cancer types in people with Parkinson's disease: a national record-linkage study. , 2014, European journal of cancer.

[22]  J. Driver.  Inverse association between cancer and neurodegenerative disease: review of the epidemiologic and biological evidence , 2014, Biogerontology.

[23]  J. Ioannidis,et al.  Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials , 2014, BMJ : British Medical Journal.

[24]  Alfonso Valencia,et al.  Molecular Evidence for the Inverse Comorbidity between Central Nervous System Disorders and Cancers Detected by Transcriptomic Meta-analyses , 2014, PLoS genetics.

[25]  Eduard Vieta,et al.  Inverse and Direct Cancer Comorbidity in People with Central Nervous System Disorders: A Meta-Analysis of Cancer Incidence in 577,013 Participants of 50 Observational Studies , 2014, Psychotherapy and Psychosomatics.

[26]  David Moher,et al.  Reducing waste from incomplete or unusable reports of biomedical research , 2014, The Lancet.

[27]  R. Tibshirani,et al.  Increasing value and reducing waste in research design, conduct, and analysis , 2014, The Lancet.

[28]  F. Catalá-López,et al.  Alzheimer's Disease and Cancer: Current Epidemiological Evidence for a Mutual Protection , 2014, Neuroepidemiology.

[29]  Eduard Vieta,et al.  The increasing burden of mental and neurological disorders , 2013, European Neuropsychopharmacology.

[30]  Carlo Caltagirone,et al.  Inverse occurrence of cancer and Alzheimer disease , 2013, Neurology.

[31]  D. Moher,et al.  Comparative effectiveness of monotherapies and combination therapies for patients with hypertension: protocol for a systematic review with network meta-analyses , 2013, Systematic Reviews.

[32]  Rafael Tabarés-Seisdedos,et al.  Inverse cancer comorbidity: a serendipitous opportunity to gain insight into CNS disorders , 2013, Nature Reviews Neuroscience.

[33]  J. Ioannidis,et al.  Evaluation of excess statistical significance in meta-analyses of 98 biomarker associations with cancer risk. , 2012, Journal of the National Cancer Institute.

[34]  J. Olsen,et al.  Malignant melanoma, breast cancer and other cancers in patients with Parkinson's disease , 2012, International journal of cancer.

[35]  S. Wyke,et al.  Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study , 2012, The Lancet.

[36]  Sudha Seshadri,et al.  Inverse association between cancer and Alzheimer’s disease: results from the Framingham Heart Study , 2012, BMJ : British Medical Journal.

[37]  R. Liu,et al.  Meta-analysis of the relationship between Parkinson disease and melanoma , 2011, Neurology.

[38]  Anaïs Baudot,et al.  No paradox, no progress: inverse cancer comorbidity in people with other complex diseases. , 2011, The Lancet. Oncology.

[39]  Richard D Riley,et al.  Interpretation of random effects meta-analyses , 2011, BMJ : British Medical Journal.

[40]  M. Clarke,et al.  Methodology in conducting a systematic review of systematic reviews of healthcare interventions , 2011, BMC medical research methodology.

[41]  P. Kinnunen.  CANCER LINKED TO ALZHEIMER DISEASE BUT NOT VASCULAR DEMENTIA , 2010, Neurology.

[42]  M. Weller,et al.  CANCER RISK AMONG PATIENTS WITH MULTIPLE SCLEROSIS AND THEIR PARENTS , 2010, Neurology.

[43]  E. Schernhammer,et al.  Parkinson’s disease and cancer risk: a systematic review and meta-analysis , 2010, Cancer Causes & Control.

[44]  John P.A. Ioannidis,et al.  Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses , 2009, Canadian Medical Association Journal.

[45]  R. Hodgson,et al.  Schizophrenia and breast cancer incidence A systematic review of clinical studies , 2009, Schizophrenia Research.

[46]  David Yeates,et al.  Cancer in patients with motor neuron disease, multiple sclerosis and Parkinson's disease: record linkage studies , 2009, Journal of Neurology, Neurosurgery & Psychiatry.

[47]  J. Hillert,et al.  Cancer risk among patients with multiple sclerosis and their parents , 2009, Neurology.

[48]  David J Spiegelhalter,et al.  A re-evaluation of random-effects meta-analysis , 2009, Journal of the Royal Statistical Society. Series A,.

[49]  K. Shojania,et al.  Surveillance search techniques identified the need to update systematic reviews. , 2008, Journal of clinical epidemiology.

[50]  Aaron D. J. Frost,et al.  Cancer incidence in patients with schizophrenia and their first‐degree relatives – a meta‐analysis , 2008, Acta psychiatrica Scandinavica.

[51]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[52]  John P A Ioannidis,et al.  Almost all articles on cancer prognostic markers report statistically significant results. , 2007, European journal of cancer.

[53]  J. Buring,et al.  A Prospective Cohort Study of Cancer Incidence Following the Diagnosis of Parkinson's Disease , 2007, Cancer Epidemiology Biomarkers & Prevention.

[54]  Xiaomei Ma,et al.  Global Burden of Cancer , 2006, The Yale journal of biology and medicine.

[55]  John P A Ioannidis,et al.  Selective reporting biases in cancer prognostic factor studies. , 2005, Journal of the National Cancer Institute.

[56]  D. Maraganore,et al.  Risk of cancer after the diagnosis of Parkinson's disease: A historical cohort study , 2005, Movement disorders : official journal of the Movement Disorder Society.

[57]  J. Miller,et al.  Alzheimer disease and cancer , 2005, Neurology.

[58]  J. Olsen,et al.  Atypical cancer pattern in patients with Parkinson's disease , 2004, British Journal of Cancer.

[59]  Matthias Egger,et al.  The scandal of poor epidemiological research , 2004, BMJ : British Medical Journal.

[60]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[61]  J. Ioannidis,et al.  Evolution of treatment effects over time: empirical insight from recursive cumulative metaanalyses. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[62]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[63]  J. Barendregt,et al.  Global burden of disease , 1997, The Lancet.

[64]  C. Begg,et al.  Operating characteristics of a rank correlation test for publication bias. , 1994, Biometrics.

[65]  T C Chalmers,et al.  Cumulative meta-analysis of therapeutic trials for myocardial infarction. , 1992, The New England journal of medicine.

[66]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[67]  W. G. Cochran.  The combination of estimates from different experiments. , 1954 .

[68]  Ashutosh Kumar Singh,et al.  Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2016, Lancet.

[69]  Ashutosh Kumar Singh,et al.  Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2016, Lancet.

[70]  Global, regional, and national incidence, prevalence, and YLDs for 301 acute and chronic diseases and injuries for 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015 .

[71]  J. Ioannidis,et al.  Potential increased risk of cancer from commonly used medications: an umbrella review of meta-analyses. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[72]  P. Tugwell,et al.  The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses , 2014 .

[73]  Katja Jasinskaja,et al.  Elaboration and Explanation ⋆ , 2011 .

[74]  E. Ponce,et al.  World Cancer Research Fund, American Institute for Cancer Research. Second Expert Report, Food, Nutrition, Physical Activity and the Prevention of Cancer: A Global Perspective. United Kingdom: WCRF/AICR, 2001 , 2009 .

[75]  P. Tugwell,et al.  Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. , 2007, BMC medical research methodology.

[76]  廣畑 富雄,et al.  Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective , 2007 .

[77]  Alan D. Lopez,et al.  The Global Burden of Disease Study , 2003 .